These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
9. Cefiderocol, a New Siderophore Cephalosporin for the Treatment of Complicated Urinary Tract Infections Caused by Multidrug-Resistant Pathogens: Preclinical and Clinical Pharmacokinetics, Pharmacodynamics, Efficacy and Safety. Lee YR; Yeo S Clin Drug Investig; 2020 Oct; 40(10):901-913. PubMed ID: 32700154 [TBL] [Abstract][Full Text] [Related]
10. Clinical Outcome of Cefiderocol for Infections with Carbapenem-Resistant Organisms. Sajib MI; Monteforte M; Go R Antibiotics (Basel); 2023 May; 12(5):. PubMed ID: 37237839 [TBL] [Abstract][Full Text] [Related]
11. Safety and efficacy of cefiderocol for off-label treatment indications: A systematic review. Babidhan R; Lewis A; Atkins C; Jozefczyk NJ; Nemecek BD; Montepara CA; Gionfriddo MR; Zimmerman DE; Covvey JR; Guarascio AJ Pharmacotherapy; 2022 Jul; 42(7):549-566. PubMed ID: 35611627 [TBL] [Abstract][Full Text] [Related]
12. In vitro activity of the novel siderophore cephalosporin, cefiderocol, in Gram-negative pathogens in Europe by site of infection. Candel FJ; Santerre Henriksen A; Longshaw C; Yamano Y; Oliver A Clin Microbiol Infect; 2022 Mar; 28(3):447.e1-447.e6. PubMed ID: 34298176 [TBL] [Abstract][Full Text] [Related]
14. Cefiderocol versus high-dose, extended-infusion meropenem for the treatment of Gram-negative nosocomial pneumonia (APEKS-NP): a randomised, double-blind, phase 3, non-inferiority trial. Wunderink RG; Matsunaga Y; Ariyasu M; Clevenbergh P; Echols R; Kaye KS; Kollef M; Menon A; Pogue JM; Shorr AF; Timsit JF; Zeitlinger M; Nagata TD Lancet Infect Dis; 2021 Feb; 21(2):213-225. PubMed ID: 33058798 [TBL] [Abstract][Full Text] [Related]
15. Cefiderocol for treatment of an empyema due to extensively drug-resistant Kufel WD; Steele JM; Riddell SW; Jones Z; Shakeraneh P; Endy TP IDCases; 2020; 21():e00863. PubMed ID: 32577400 [TBL] [Abstract][Full Text] [Related]
16. Susceptibility Testing Is Key for the Success of Cefiderocol Treatment: A Retrospective Cohort Study. Bleibtreu A; Dortet L; Bonnin RA; Wyplosz B; Sacleux SC; Mihaila L; Dupont H; Junot H; Bunel V; Grall N; Razazi K; Duran C; Tattevin P; Dinh A; The Cefiderocol French Study Group OBO Microorganisms; 2021 Jan; 9(2):. PubMed ID: 33573148 [TBL] [Abstract][Full Text] [Related]
17. Real-life Data on Cefiderocol Efficacy and Safety to Treat Multidrug-Resistant Campogiani L; Crea AMA; Minardi ML; Ansaldo L; Coppola L; Compagno M; Vitale P; Spalliera I; Malagnino V; Teti E; D'agostini C; Pennacchiotti C; Abate DN; Celeste MG; Andreoni M; Iannetta M; Sarmati L Open Forum Infect Dis; 2023 Dec; 10(12):ofad627. PubMed ID: 38156051 [TBL] [Abstract][Full Text] [Related]
18. Real-Life Data on the Effectiveness and Safety of Cefiderocol in Severely Infected Patients: A Case Series. Fendian ÁM; Albanell-Fernández M; Tuset M; Pitart C; Castro P; Soy D; Bodro M; Soriano A; Del Río A; Martínez JA Infect Dis Ther; 2023 Apr; 12(4):1205-1216. PubMed ID: 36943617 [TBL] [Abstract][Full Text] [Related]
19. Compassionate Use of Cefiderocol in the Treatment of an Intraabdominal Infection Due to Multidrug-Resistant Pseudomonas aeruginosa: A Case Report. Stevens RW; Clancy M Pharmacotherapy; 2019 Nov; 39(11):1113-1118. PubMed ID: 31550054 [TBL] [Abstract][Full Text] [Related]
20. Prospective role of cefiderocol in the management of carbapenem-resistant Acinetobacter baumannii infections: Review of the evidence. Kollef M; Dupont H; Greenberg DE; Viale P; Echols R; Yamano Y; Nicolau DP Int J Antimicrob Agents; 2023 Aug; 62(2):106882. PubMed ID: 37301312 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]